ArticleKidney cancer journal : official journal of the Kidney Cancer Association2020
What morphology can teach us about renal cell carcinoma clonal evolution.
Article in Kidney cancer journal : official journal of the Kidney Cancer Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- The seventh kidney cancer research summit: progress in accelerating cures.The oncologist · 2026Article
- Determinants of pancreatic tropism in metastatic renal cell carcinoma.JCI insight · 2026Article
- HMGA2 links morphological evolution and microenvironment dynamics to systemic therapy response in clear cell renal cell carcinoma.Journal for immunotherapy of cancer · 2025Article
- MorphoITH: a framework for deconvolving intra-tumor heterogeneity using tissue morphology.Genome medicine · 2025Article
- Article
- Determinants of late metastases in renal cell carcinoma.Journal of the National Cancer Institute · 2025Article
- Comparison of Histologic Parameters and Predictive Gene Signatures in Clear Cell Renal Cell Carcinoma Response to Systemic Therapy.Pathology international · 2025Article
- Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial.Nature communications · 2025Article
- Association of Histologic Growth Patterns and Some Histopathologic Features in Clear Cell Renal Cell Carcinoma with Patient's Survival after Nephrectomy: A Cross-Sectional Study.Iranian journal of pathology · 2025Article
- Histopathology Based AI Model Predicts Anti-Angiogenic Therapy Response in Renal Cancer Clinical Trial.ArXiv · 2024Article
- The expanding role of BAP1 in clear cell renal cell carcinoma.Human pathology · 2023Review
- Predicting Oncologic Outcomes in Small Renal Tumors.European urology oncology · 2022Article
- Intratumoral Resolution of Driver Gene Mutation Heterogeneity in Renal Cancer Using Deep Learning.Cancer research · 2022Article
- Development and validation of a vascularity-based architectural classification for clear cell renal cell carcinoma: correlation with conventional pathological prognostic factors, gene expression patterns, and clinical outcomes.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- Article
- Improving Renal Tumor Biopsy Prognostication With BAP1 Analyses.Archives of pathology & laboratory medicine · 2022Article
- Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma.Journal of cancer metastasis and treatment · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
While cancer is a clonal process, cumulative evidence suggest that tumors are rather heterogenous and are composed of multiple genetically-distinct subclones that arise at different times and either persist and co-exist, expand and evolve, or are eliminated. A paradigm of tumor heterogeneity is renal cell carcinoma (RCC). By exploiting morphological traits and building upon a framework around three axes (architecture, cytology and the microenvironment), we review recent advances in our understanding of RCC evolution leading to an integrated molecular genetic and morphologic evolutionary model with both prognostic and therapeutic implications. The ability to predict cancer evolution may have profound implications for clinical care and is central to oncology.
Indexed as
Identifiers
34178206PMC8232548What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.